Ivana Peran1, Sivanesan Dakshanamurthy2, Matthew D McCoy3, Anastasia Mavropoulos4, Bedilu Allo5, Aimy Sebastian6, Nicholas R Hum7, Sara C Sprague2, Kelly A Martin6, Michael J Pishvaian2, Eveline E Vietsch2, Anton Wellstein2, Michael B Atkins2, Louis M Weiner2, Andrew A Quong4, Gabriela G Loots8, Stephen S Yoo9, Shahin Assefnia10, Stephen W Byers11. 1. Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia. Electronic address: ip62@georgetown.edu. 2. Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia. 3. Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia; Innovation Center for Biomedical Informatics, Georgetown University, Washington, District of Columbia. 4. Fluidigm Corporation, South San Francisco, California. 5. Fluidigm Canada, Inc, Markham, Ontario, Canada. 6. Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California. 7. Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California; School of Natural Sciences, University of California Merced, Merced, California. 8. Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California; School of Natural Sciences, University of California Merced, Merced, California; Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California. 9. STCube Pharmaceuticals, Inc, Gaithersburg, Maryland. 10. Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia. Electronic address: sa358@georgetown.edu. 11. Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia. Electronic address: byerss@georgetown.edu.
Abstract
BACKGROUND & AIMS: Pancreatic ductal adenocarcinomas (PDACs) are characterized by fibrosis and an abundance of cancer-associated fibroblasts (CAFs). We investigated strategies to disrupt interactions among CAFs, the immune system, and cancer cells, focusing on adhesion molecule CDH11, which has been associated with other fibrotic disorders and is expressed by activated fibroblasts. METHODS: We compared levels of CDH11 messenger RNA in human pancreatitis and pancreatic cancer tissues and cells with normal pancreas, and measured levels of CDH11 protein in human and mouse pancreatic lesions and normal tissues. We crossed p48-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ (KPC) mice with CDH11-knockout mice and measured survival times of offspring. Pancreata were collected and analyzed by histology, immunohistochemistry, and (single-cell) RNA sequencing; RNA and proteins were identified by imaging mass cytometry. Some mice were given injections of PD1 antibody or gemcitabine and survival was monitored. Pancreatic cancer cells from KPC mice were subcutaneously injected into Cdh11+/+ and Cdh11-/- mice and tumor growth was monitored. Pancreatic cancer cells (mT3) from KPC mice (C57BL/6), were subcutaneously injected into Cdh11+/+ (C57BL/6J) mice and mice were given injections of antibody against CDH11, gemcitabine, or small molecule inhibitor of CDH11 (SD133) and tumor growth was monitored. RESULTS: Levels of CDH11 messenger RNA and protein were significantly higher in CAFs than in pancreatic cancer epithelial cells, human or mouse pancreatic cancer cell lines, or immune cells. KPC/Cdh11+/- and KPC/Cdh11-/- mice survived significantly longer than KPC/Cdh11+/+ mice. Markers of stromal activation entirely surrounded pancreatic intraepithelial neoplasias in KPC/Cdh11+/+ mice and incompletely in KPC/Cdh11+/- and KPC/Cdh11-/- mice, whose lesions also contained fewer FOXP3+ cells in the tumor center. Compared with pancreatic tumors in KPC/Cdh11+/+ mice, tumors of KPC/Cdh11+/- mice had increased markers of antigen processing and presentation; more lymphocytes and associated cytokines; decreased extracellular matrix components; and reductions in markers and cytokines associated with immunosuppression. Administration of the PD1 antibody did not prolong survival of KPC mice with 0, 1, or 2 alleles of Cdh11. Gemcitabine extended survival of KPC/Cdh11+/- and KPC/Cdh11-/- mice only or reduced subcutaneous tumor growth in mT3 engrafted Cdh11+/+ mice when given in combination with the CDH11 antibody. A small molecule inhibitor of CDH11 reduced growth of pre-established mT3 subcutaneous tumors only if T and B cells were present in mice. CONCLUSIONS: Knockout or inhibition of CDH11, which is expressed by CAFs in the pancreatic tumor stroma, reduces growth of pancreatic tumors, increases their response to gemcitabine, and significantly extends survival of mice. CDH11 promotes immunosuppression and extracellular matrix deposition, and might be developed as a therapeutic target for pancreatic cancer.
BACKGROUND & AIMS: Pancreatic ductal adenocarcinomas (PDACs) are characterized by fibrosis and an abundance of cancer-associated fibroblasts (CAFs). We investigated strategies to disrupt interactions among CAFs, the immune system, and cancer cells, focusing on adhesion molecule CDH11, which has been associated with other fibrotic disorders and is expressed by activated fibroblasts. METHODS: We compared levels of CDH11 messenger RNA in human pancreatitis and pancreatic cancer tissues and cells with normal pancreas, and measured levels of CDH11 protein in human and mouse pancreatic lesions and normal tissues. We crossed p48-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ (KPC) mice with CDH11-knockout mice and measured survival times of offspring. Pancreata were collected and analyzed by histology, immunohistochemistry, and (single-cell) RNA sequencing; RNA and proteins were identified by imaging mass cytometry. Some mice were given injections of PD1 antibody or gemcitabine and survival was monitored. Pancreatic cancer cells from KPC mice were subcutaneously injected into Cdh11+/+ and Cdh11-/- mice and tumor growth was monitored. Pancreatic cancer cells (mT3) from KPC mice (C57BL/6), were subcutaneously injected into Cdh11+/+ (C57BL/6J) mice and mice were given injections of antibody against CDH11, gemcitabine, or small molecule inhibitor of CDH11 (SD133) and tumor growth was monitored. RESULTS: Levels of CDH11 messenger RNA and protein were significantly higher in CAFs than in pancreatic cancer epithelial cells, human or mouse pancreatic cancer cell lines, or immune cells. KPC/Cdh11+/- and KPC/Cdh11-/- mice survived significantly longer than KPC/Cdh11+/+ mice. Markers of stromal activation entirely surrounded pancreatic intraepithelial neoplasias in KPC/Cdh11+/+ mice and incompletely in KPC/Cdh11+/- and KPC/Cdh11-/- mice, whose lesions also contained fewer FOXP3+ cells in the tumor center. Compared with pancreatic tumors in KPC/Cdh11+/+ mice, tumors of KPC/Cdh11+/- mice had increased markers of antigen processing and presentation; more lymphocytes and associated cytokines; decreased extracellular matrix components; and reductions in markers and cytokines associated with immunosuppression. Administration of the PD1 antibody did not prolong survival of KPC mice with 0, 1, or 2 alleles of Cdh11. Gemcitabine extended survival of KPC/Cdh11+/- and KPC/Cdh11-/- mice only or reduced subcutaneous tumor growth in mT3 engrafted Cdh11+/+ mice when given in combination with the CDH11 antibody. A small molecule inhibitor of CDH11 reduced growth of pre-established mT3 subcutaneous tumors only if T and B cells were present in mice. CONCLUSIONS: Knockout or inhibition of CDH11, which is expressed by CAFs in the pancreatic tumor stroma, reduces growth of pancreatic tumors, increases their response to gemcitabine, and significantly extends survival of mice. CDH11 promotes immunosuppression and extracellular matrix deposition, and might be developed as a therapeutic target for pancreatic cancer.
Authors: Davendra P S Sohal; Erin B Kennedy; Alok Khorana; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Ramesh K Ramanathan; Joseph T Ruggiero; Manish A Shah; Susan Urba; Hope E Uronis; Michelle W Lau; Daniel Laheru Journal: J Clin Oncol Date: 2018-05-23 Impact factor: 44.544
Authors: Sook Kyung Chang; Ayano C Kohlgruber; Fumitaka Mizoguchi; Xavier Michelet; Benjamin J Wolf; Kevin Wei; Pui Y Lee; Lydia Lynch; Danielle Duquette; Victòria Ceperuelo-Mallafré; Alexander S Banks; Michael B Brenner Journal: J Clin Invest Date: 2017-07-31 Impact factor: 14.808
Authors: Vegard Tjomsland; Anna Spångeus; Johanna Välilä; Per Sandström; Kurt Borch; Henrik Druid; Sture Falkmer; Ursula Falkmer; Davorka Messmer; Marie Larsson Journal: Neoplasia Date: 2011-08 Impact factor: 5.715
Authors: Christine A Iacobuzio-Donahue; Anirban Maitra; Grace L Shen-Ong; Tjarda van Heek; Raheela Ashfaq; Renee Meyer; Kimberly Walter; Karin Berg; Michael A Hollingsworth; John L Cameron; Charles J Yeo; Scott E Kern; Michael Goggins; Ralph H Hruban Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Christine A Iacobuzio-Donahue; Anirban Maitra; Mari Olsen; Anson W Lowe; N Tjarda van Heek; Christophe Rosty; Kim Walter; Norihiro Sato; Antony Parker; Raheela Ashfaq; Elizabeth Jaffee; Byungwoo Ryu; Jessa Jones; James R Eshleman; Charles J Yeo; John L Cameron; Scott E Kern; Ralph H Hruban; Patrick O Brown; Michael Goggins Journal: Am J Pathol Date: 2003-04 Impact factor: 4.307
Authors: Jorge Blando; Anu Sharma; Maria Gisela Higa; Hao Zhao; Luis Vence; Shalini S Yadav; Jiseong Kim; Alejandro M Sepulveda; Michael Sharp; Anirban Maitra; Jennifer Wargo; Michael Tetzlaff; Russell Broaddus; Matthew H G Katz; Gauri R Varadhachary; Michael Overman; Huamin Wang; Cassian Yee; Chantale Bernatchez; Christine Iacobuzio-Donahue; Sreyashi Basu; James P Allison; Padmanee Sharma Journal: Proc Natl Acad Sci U S A Date: 2019-01-11 Impact factor: 12.779
Authors: Christine M Costello; Nancy Mah; Robert Häsler; Philip Rosenstiel; Georg H Waetzig; Andreas Hahn; Tim Lu; Yesim Gurbuz; Susanna Nikolaus; Mario Albrecht; Jochen Hampe; Ralph Lucius; Günther Klöppel; Holger Eickhoff; Hans Lehrach; Thomas Lengauer; Stefan Schreiber Journal: PLoS Med Date: 2005-08-23 Impact factor: 11.069
Authors: Nezihi Murat Karabacak; Yu Zheng; Taronish D Dubash; Risa Burr; Douglas S Micalizzi; Ben S Wittner; Maoxuan Lin; Devon F Wiley; Valentine Comaills; Erin Emmons; Kira L Niederhoffer; Uyen Ho; Jacob Ukleja; Dante Che; Hannah Stowe; Linda T Nieman; Wilhelm Haas; Shannon L Stott; Michael S Lawrence; David T Ting; David T Miyamoto; Daniel A Haber; Mehmet Toner; Shyamala Maheswaran Journal: Cancer Res Date: 2022-03-15 Impact factor: 13.312
Authors: Yalan Lei; Rong Tang; Jin Xu; Wei Wang; Bo Zhang; Jiang Liu; Xianjun Yu; Si Shi Journal: J Hematol Oncol Date: 2021-06-09 Impact factor: 17.388